Tag Archives: Certain

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

BOSTON–(BUSINESS WIRE)–Jun. 9, 2021– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a… Read More »

Minorities Rarely Shown in TV Ads for Meds That Treat Certain Skin Conditions

While people of color commonly suffer from psoriasis and eczema, they are less likely to be portrayed in TV commercials for medications that target these skin conditions. This underrepresentation may contribute to unconscious bias among clinicians and unawareness of treatment options among patients, suggest new findings published in the journal Cutis, reports Penn Medicine News.… Read More »

Hispanics in Certain Counties More Likely to Die from Heart Disease, Stroke

(Juanmonino/Getty Images) Hispanic adults who live in counties with high concentrations of their ethnic peers are about 60 percent more likely than those who don’t to die from heart disease and stroke, a new study shows. As a group, Hispanics have lower death rates from heart disease and stroke than white and black adults –… Read More »

FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Print this page KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.– September 17, 2019 — (BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima, the orally available kinase inhibitor discovered by… Read More »